title: Treatment of refractory acute lymphoblastic leukemia with teniposide and cytarabine.
authors.forename: B A
authors.initials: BA
authors.lastname: Kamen
authors.forename: J
authors.initials: J
authors.lastname: Casper
authors.forename: S
authors.initials: S
authors.lastname: Lauer
authors.forename: B M
authors.initials: BM
authors.lastname: Camitta
authors.forename: J S
authors.initials: JS
authors.lastname: Holcenberg
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D013713:Teniposide / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D013713:Teniposide; D008727:Methotrexate